Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study On Monday, Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results